公开(公告)号：WO2023091900A1

公开(公告)日：2023-05-25

申请号：PCT/US2022/079847

申请日：2022-11-15

Applicant: DUKE UNIVERSITY

Inventor： LEFKOWITZ, Robert ,  ROCKMAN, Howard ,  AHN, Seungkiri ,  PANI, Biswaranjan ,  WANG, Jialu ,  KAHSAI, Alem

IPC: A61K31/403 ,  C07C311/16

Abstract: The present disclosure provides compositions that provide positive allosteric modulator compounds of the beta-adrenergic receptor in combination with a beta-arrestin-biased beta-blocker, such as carvedilol, for the treatment of cardiovascular diseases and disorders, such as hypertension and heart failure, wherein the effectiveness of the beta-blocker is enhanced by positively augmenting carvedilol-stimulated cellular responses.

公开(公告)号：WO2023081845A1

公开(公告)日：2023-05-11

申请号：PCT/US2022/079334

申请日：2022-11-04

Applicant: GEORGIAMUNE LLC

Inventor： KHLEIF, Samir ,  MKRTICHYAN, Mikayel ,  MACCOSS, Malcolm

IPC: A61K31/33 ,  A61K31/435 ,  A61K31/4545 ,  A61K31/403

Abstract: Compounds of Formula (Ia), (Ib), or (Ic), are described, where the various substituents are defined herein. The compounds can modulate a property or effect of Akt3 in vitro or in vivo, and can also be used, individually or in combination with other agents, in the prevention or treatment of a variety of conditions. Methods for synthesizing the compounds are described. Pharmaceutical compositions and methods of using these compounds or compositions, individually or in combination with other agents or compositions, in the prevention or treatment of a variety of conditions are also described.

公开(公告)号：WO2023081665A1

公开(公告)日：2023-05-11

申请号：PCT/US2022/079093

申请日：2022-11-01

Applicant: ARIA PHARMACEUTICALS, INC.

Inventor： PANDEY, Anjali ,  KALITA, Biswajit ,  DURAISWAMY, Athisayamani Jeyaraj

IPC: A61P27/00 ,  A61P37/00 ,  C07D209/96 ,  C07D487/10 ,  A61K31/403

Abstract: The present disclosure relates generally to small molecule modulators of chemotactic cytokines (chemokine) receptors CCR2, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.

公开(公告)号：WO2023076679A1

公开(公告)日：2023-05-04

申请号：PCT/US2022/048434

申请日：2022-10-31

Applicant: ALKAHEST, INC.

Inventor： CAMPBELL, Meghan Kerrisk ,  CZIRR, Eva ,  HARISH, Reema

IPC: A61K31/33 ,  A61K31/335 ,  A61K31/357 ,  A61K31/403

Abstract: This invention pertains to the prevention and treatment of aging-associated disease. The invention relates to the use of benzodioxane inhibitors of leukotriene production through modulation of leukotriene A4 hydrolase ("LTA4H") to treat and/or prevent conditions associated with aging such as cognitive disorders, motor disorders, and neuroinflammation.

公开(公告)号：WO2023047203A1

公开(公告)日：2023-03-30

申请号：PCT/IB2022/057529

申请日：2022-08-12

Applicant: TORRENT PHARMACEUTICALS LTD

Inventor： DUTT, Chaitanya ,  JOSHI, Deepa ,  SINGH, Amarinder ,  JAMADARKHANA, Prashant ,  SRIVASTAVA, Sanjay ,  SHAH, Apurva ,  KULKARNI, Amol ,  MATHUR, Anoop ,  PARIKH, Siralee ,  RAI, Deepak

IPC: A61K31/401 ,  A61K31/403 ,  A61K31/415 ,  A61K31/4178 ,  A61K31/4184 ,  A61K45/06 ,  A61P3/06 ,  A61P3/10 ,  A61P9/12

Abstract: Present invention relates to combination comprising omzotirome and one or more antidiabetic agent, antihypertensive agent and/or anti-dyslipidemic agent and use of such combination for managing cardio-metabolic based chronic diseases by improving glycemic control, blood pressure control and/or lipid control in a patient in recognized need thereof. Present invention also relates to a pharmaceutical composition comprising omzotirome and one or more of antidiabetic agent, antihypertensive agent and/or anti-dyslipidemic agent; and to a method of managing cardio-metabolic based chronic disease by improving glycemic control, blood pressure control and/or lipid control in a patient in recognized need thereof by administering such pharmaceutical composition.

公开(公告)号：WO2022240810A1

公开(公告)日：2022-11-17

申请号：PCT/US2022/028488

申请日：2022-05-10

Applicant: BIOGEN MA INC.

Inventor： NISHIMURA, Naoko ,  HASUMI, Keiji ,  HONDA, Kazuo

IPC: A61K31/403 ,  A61P7/04 ,  A61P9/10

Abstract: To provide a safe and effective therapy and pharmaceutical composition using SMTP-7 (Compound I) or a salt thereof in cerebral infarction patients. A pharmaceutical composition for treating cerebral infarction, comprising SMTP-7 (Compound I) or a pharmacological acceptable salt thereof, which is administered at a dose of 1 to 6 mg/kg as SMTP-7 (Compound I) or a salt thereof.

公开(公告)号：WO2022238779A1

公开(公告)日：2022-11-17

申请号：PCT/IB2022/053323

申请日：2022-04-08

Applicant: UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA"

Inventor： BARONE, Eugenio ,  TRAMUTOLA, Antonella ,  PERLUIGI, Marzia

IPC: A61K31/40 ,  A61K31/4162 ,  A61K31/495 ,  A61K31/496 ,  A61K31/506 ,  A61K31/519 ,  A61P25/00 ,  A61P25/28 ,  A61K31/403 ,  A61K31/4164 ,  A61K31/4985 ,  A61K31/522 ,  A61K31/69

Abstract: Composition for use in the prevention and/or in the treatment of intellectual disability and neurodegenerative diseases in a subject with Down syndrome, wherein the composition comprises as an active agent at least one compound belonging to the class of dipeptidyl-peptidase IV (DPP4) enzyme inhibitors and also to the class of gliptins.

公开(公告)号：WO2022232391A1

公开(公告)日：2022-11-03

申请号：PCT/US2022/026729

申请日：2022-04-28

Applicant: DANA-FARBER CANCER INSTITUTE, INC.

Inventor： ZHANG, Tinghu ,  JONES, Lyn Howard ,  LIU, Hu ,  CHE, Jianwei

IPC: A61K31/403 ,  A61K31/4035 ,  A61K31/445 ,  C07D209/48 ,  C07D401/00 ,  C07D401/14

Abstract: Disclosed are compounds and pharmaceutically acceptable salts and stereoisomers thereof that may bind to CRBN complex and cause degradation of various proteins e.g., IKZF2 (Helios). Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds to treat diseases and disorders characterized or mediated by the presence of a protein, and hence would benefit from degradation of said protein.

公开(公告)号：WO2022214889A1

公开(公告)日：2022-10-13

申请号：PCT/IB2022/052188

申请日：2022-03-11

Applicant: UNIVERSITATSSPITAL BASEL

Inventor： LIECHTI, Matthias Emanuel

IPC: A61K31/137 ,  A61K31/403 ,  A61P39/00

Abstract: A composition for treating an individual while reducing acute adverse effects of an empathogen/entactogen, including effective amounts of the empathogen/entactogen and an adverse effect-reducing agent that blocks adverse effects of the empathogen/entactogen. A method of treating an individual with an empathogen/entactogen and reducing its acute adverse effects, by administering an empathogen/entactogen to the individual, administering an adverse effect-reducing agent to the individual, and reducing the acute adverse effects of the empathogen/entactogen. A method of stopping the acute cardlostimulant and hyperthermic action of an empathogen/entactogen in an individual, by administering an adverse effect-reducing agent to the individual after the individual has taken the empathogen/entactogen and stopping the acute adverse effects of the empathogen/entactogen, A method of treating an individual at risk of cardiovascular events and/or hyperthermia with an empathogen/entactogen.

公开(公告)号：WO2022197567A1

公开(公告)日：2022-09-22

申请号：PCT/US2022/020084

申请日：2022-03-12

Applicant: PURDUE RESEARCH FOUNDATION

Inventor： LOW, Philip, Stewart ,  MUKKAMALA, Ramesh ,  SRINIVASARAO, Madduri ,  LINDEMAN, Spencer, D.

IPC: A61K31/403 ,  A61K31/4035 ,  C07D209/02 ,  C07D209/44

Abstract: Fibroblast activation protein (FAP)-targeting compounds; methods for imaging cancer and fibrosis; and methods for treating fibrosis, an inflammatory disease/disorder, and cancer.